Efficient gene expression by self-complementary adeno-associated virus serotype 2 and 5 in various human cancer cells

Oncology Reports

Volumn 18, Issue 3, 2007, Pages 611-616

  Lee, Han Saem ^a   Shin, Oh Kyo ^a   Kim, Sung Jin ^a   Lee, Won Il ^a   Jeong, Sunjoo ^b   Park, Keerang ^c   Choe, Han ^a   Lee, Heuiran ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Dankook University   (South Korea)

^c Juseong College   (South Korea)

Author keywords

Human cancer cells; Persistence; Self complementary recombinant adeno associated virus; Serotype; Transduction efficiency

Indexed keywords

GREEN FLUORESCENT PROTEIN; PRIMER DNA;

ADENO ASSOCIATED VIRUS; ARTICLE; CLASSIFICATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; NEOPLASM; REPORTER GENE; SEROTYPING; TUMOR CELL LINE; VIROLOGY;

CELL LINE, TUMOR; DEPENDOVIRUS; DNA PRIMERS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HUMANS; NEOPLASMS; SEROTYPING;

EID: 34447275268     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.3.611     Document Type: Article

References (57)

1. Li C, Bowles DE, van Dyke T and Samulski RJ: Adeno-associated virus vectors: Potential applications for cancer gene therapy. Cancer Gene Ther 12: 913-925, 2005. (Pubitemid 41622258)
2. Hacker UT, Wingenfeld L, Kofler DM, et al: Adeno-associated virus serotypes 1-5 mediated tumor cell directed gene transfer and improvement of transduction efficiency. J Gene Med 7: 1429-1438, 2005. (Pubitemid 41672401)
3. Berns KI, Muzyczka N, Knipe DM and Howley PM: Field's virology. Vol. 2. 4th edition. Lippincott-Raven, Philadelphia, PA, pp2327-2359, 2001.
4. Kotin RM, Siniscalco M, Samulski RJ, et al: Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 87: 2211-2215, 1990.
5. Rivadeneira ED, Popescu NC, Zimonjic DB, et al: Sites of recombinant adeno-associated virus integration. Int J Oncol 12: 805-810, 1998. (Pubitemid 28133571)
6. Watanabe M, Nasu Y, Kashiwakura Y, et al: Adeno-associated virus 2-mediated intratumoral prostate cancer gene therapy: long-term maspin expression efficiently suppresses tumor growth. Hum Gene Ther 16: 699-710, 2005. (Pubitemid 40864270)
7. Kim SJ, Nam YR, Shin O, et al: Treatment with hydroxyurea and tyrphostin-1 significantly improves the transduction efficiency of recombinant adeno-associated viruses in human cancer cells. Oncol Rep 14: 1475-1479, 2005.
8. McCarty DM, Fu H, Monahan PE, Toulson CE, Naik P and Samulski RJ: Adeno-associated virus terminal repeat (tr) mutant generates self-complementary vectors to overcome the ratelimiting step to transduction in vivo. Gene Ther 10: 2112-2118, 2003. (Pubitemid 37536760)
9. McCarty DM, Monahan PE and Samulski RJ: Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 8: 1248-1254, 2001. (Pubitemid 32780813)
10. Wang Z, Ma HI, Li J, Sun L, Zhang J and Xiao X: Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 10: 2105-2111, 2003. (Pubitemid 37536759)
11. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J and Wilson JM: Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99: 11854-11859, 2002. (Pubitemid 34994488)
12. Gao G, Vandenberghe LH and Wilson JM: New recombinant serotypes of AAV vectors. Curr Gene Ther 5: 285-297, 2005. (Pubitemid 40895013)
13. Grimm D and Kay MA: From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther 3: 281-304, 2003.
14. Blankinship MJ, Gregorevic P, Allen JM, et al: Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol Ther 10: 671-678, 2004. (Pubitemid 39272856)
15. Louboutin JP, Wang L and Wilson JM: Gene transfer into skeletal muscle using novel AAV serotypes. J Gene Med 7: 442-451, 2005. (Pubitemid 40553125)
16. Su H, Huang Y, Takagawa J, et al: Aav serotype-1 mediates early onset of gene expression in mouse hearts and results in better therapeutic effect. Gene Ther 13: 1495-1502, 2006. (Pubitemid 44567147)
17. Wang Z, Zhu T, Qiao C, et al: Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 23: 321-328, 2005. (Pubitemid 41094420)
18. Chen S, Kapturczak M, Loiler SA, et al: Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors. Hum Gene Ther 16: 235-247, 2005. (Pubitemid 40344215)
19. Song JJ, Kim JH, Lee H, et al: Enhancement of gene transfer efficiency into human cancer cells by modification of retroviral vectors and addition of chemicals. Oncol Rep 7: 119-124, 2000.
20. Nam YR, Kim SJ, Lee B, et al: Analysis of the production efficiency and titration of various recombinant adeno-associated viruses. Oncol Rep 12: 761-766, 2004.
21. Moon MS, Joo CH, Hwang IS, et al: Distribution of viral rna in mouse tissues during acute phase of coxsackievirus b5 infection. Intervirology 48: 153-160, 2005.
22. Russell DW, Alexander IE and Miller AD: DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc Natl Acad Sci USA 92: 5719-5723, 1995.
23. Smith AD, Collaco RF and Trempe JP: Enhancement of recombinant adeno-associated virus type 2-mediated transgene expression in a lung epithelial cell line by inhibition of the epidermal growth factor receptor. J Virol 77: 6394-6404, 2003. (Pubitemid 36588410)
24. Douar AM, Poulard K, Stockholm D and Danos O: Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J Virol 75: 1824-1833, 2001. (Pubitemid 32110172)
25. Mochizuki S, Mizukami H, Ogura T, et al: Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria mice. Gene Ther 11: 1081-1086, 2004. (Pubitemid 39023112)
26. Subramanian IV, Bui Nguyen TM, Truskinovsky AM, Tolar J, Blazar BR and Ramakrishnan S: Adeno-associated virus-mediated delivery of a mutant endostatin in combination with carboplatin treatment inhibits orthotopic growth of ovarian cancer and improves long-term survival. Cancer Res 66: 4319-4328, 2006.
27. Duan D, Fisher KJ, Burda JF and Engelhardt JF: Structural and functional heterogeneity of integrated recombinant AAV genomes. Virus Res 48: 41-56, 1997. (Pubitemid 27163268)
28. Miller DG, Rutledge EA and Russell DW: Chromosomal effects of adeno-associated virus vector integration. Nat Genet 30: 147-148, 2002.
29. Snyder RO, Spratt SK, Lagarde C, et al: Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum Gene Ther 8: 1891-1900, 1997. (Pubitemid 27499662)
30. Fisher KJ, Jooss K, Alston J, et al: Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 3: 306-312, 1997. (Pubitemid 27112928)
31. Schnepp BC, Jensen RL, Chen CL, Johnson PR and Clark KR: Characterization of adeno-associated virus genomes isolated from human tissues. J Virol 79: 14793-14803, 2005. (Pubitemid 41636277)
32. Russell DW: AAV loves an active genome. Nat Genet 34: 241-242, 2003.
33. Haberman RP, McCown TJ and Samulski RJ: Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A/D junction element. J Virol 74: 8732-8739, 2000. (Pubitemid 30666724)
34. Bell P, Wang L, Lebherz C, et al: No evidence for tumorigenesis of AAV vectors in a large-scale study in mice. Mol Ther 12: 299-306, 2005. (Pubitemid 41025100)
35. Kay MA and Nakai H: Looking into the safety of AAV vectors. Nature 424: 251, 2003.
36. Wagner JA, Nepomuceno IB, Messner AH, et al: A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Ther 13: 1349-1359, 2002. (Pubitemid 35034514)
37. McPhee SW, Janson CG, Li C, et al: Immune responses to AAV in a phase I study for Canavan disease. J Gene Med 8: 577-588, 2006. (Pubitemid 43827251)
38. Summerford C and Samulski RJ: Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72: 1438-1445, 1998. (Pubitemid 28116931)
39. Qing K, Mah C, Hansen J, Zhou S, Dwarki V and Srivastava A: Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 5: 71-77, 1999. (Pubitemid 29051001)
40. Summerford C, Bartlett JS and Samulski RJ: Alphavbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 5: 78-82, 1999. (Pubitemid 29051002)
41. Kashiwakura Y, Tamayose K, Iwabuchi K, et al: Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J Virol 79: 609-614, 2005. (Pubitemid 39648414)
42. Akache B, Grimm D, Pandey K, Yant SR, Xu H and Kay MA: The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3 and 9. J Virol 80: 9831-9836, 2006. (Pubitemid 44435657)
43. Kaludov N, Brown KE, Walters RW, Zabner J and Chiorini JA: Adeno-associated virus serotype 4 (aav4) and aav5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol 75: 6884-6893, 2001. (Pubitemid 32641575)
44. Walters RW, Yi SM, Keshavjee S, et al: Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem 276: 20610-20616, 2001.
45. Di Pasquale G, Davidson BL, Stein CS, et al: Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 9: 1306-1312, 2003. (Pubitemid 37279855)
46. Ding W, Zhang L, Yan Z and Engelhardt JF: Intracellular trafficking of adeno-associated viral vectors. Gene Ther 12: 873-880, 2005. (Pubitemid 40852205)
47. Blacklow NR, Hoggan MD, Sereno MS, et al: A seroepidemiologic study of adenovirus-associated virus infection in infants and children. Am J Epidemiol 94: 359-366, 1971.
48. Blacklow NR, Hoggan MD and Rowe WP: Serologic evidence for human infection with adenovirus-associated viruses. J Natl Cancer Inst 40: 319-327, 1968.
49. Erles K, Sebokova P and Schlehofer JR: Update on the prevalence of serum antibodies (igg and igm) to adeno-associated virus (aav). J Med Virol 59: 406-411, 1999. (Pubitemid 29468085)
50. Chirmule N, Propert K, Magosin S, Qian Y, Qian R and Wilson J: Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6: 1574-1583, 1999. (Pubitemid 29465516)
51. Tobiasch E, Burguete T, Klein-Bauernschmitt P, Heilbronn R and Schlehofer JR: Discrimination between different types of human adeno-associated viruses in clinical samples by pcr. J Virol Methods 71: 17-25, 1998. (Pubitemid 28202292)
52. Halbert CL, Miller AD, McNamara S, et al: Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5 and 6 in cystic fibrosis and normal populations: implications for gene therapy using aav vectors. Hum Gene Ther 17: 440-447, 2006.
53. Hildinger M, Auricchio A, Gao G, Wang L, Chirmule N and Wilson JM: Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer. J Virol 75: 6199-6203, 2001. (Pubitemid 32553151)
54. Kuck D, Lau T, Leuchs B, et al: Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 l1. J Virol 80: 2621-2630, 2006. (Pubitemid 43346358)
55. Zacchigna S, Zentilin L, Morini M, et al: Aav-mediated gene transfer of tissue inhibitor of metalloproteinases-1 inhibits vascular tumor growth and angiogenesis in vivo. Cancer Gene Ther 11: 73-80, 2004. (Pubitemid 38057817)
56. Li J, Zhou J, Chen G, et al: Inhibition of ovarian cancer metastasis by adeno-associated virus-mediated gene transfer of nm23h1 in an orthotopic implantation model. Cancer Gene Ther 13: 266-272, 2006. (Pubitemid 43255763)
57. Fang J, Qian JJ, Yi S, et al: Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 23: 584-590, 2005. (Pubitemid 41724897)